ArticleAdvances in therapy2021

Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.

Joseph A Lasky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.